Landscape Capital Management L.L.C. Makes New $699,000 Investment in Biohaven Ltd. (NYSE:BHVN)

Landscape Capital Management L.L.C. purchased a new stake in Biohaven Ltd. (NYSE:BHVN) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 18,710 shares of the company’s stock, valued at approximately $699,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in BHVN. Captrust Financial Advisors purchased a new position in Biohaven in the third quarter worth approximately $293,000. HighTower Advisors LLC acquired a new position in shares of Biohaven in the 3rd quarter valued at $276,000. Wellington Management Group LLP grew its holdings in shares of Biohaven by 600.9% during the 3rd quarter. Wellington Management Group LLP now owns 243,167 shares of the company’s stock worth $12,151,000 after purchasing an additional 208,472 shares during the period. XTX Topco Ltd raised its holdings in Biohaven by 278.5% in the 3rd quarter. XTX Topco Ltd now owns 32,510 shares of the company’s stock valued at $1,625,000 after buying an additional 23,921 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Biohaven in the 3rd quarter valued at about $1,339,000. Institutional investors and hedge funds own 88.78% of the company’s stock.

Biohaven Stock Performance

Shares of Biohaven stock opened at $18.54 on Monday. The business has a 50-day simple moving average of $33.40 and a 200-day simple moving average of $40.82. The company has a market cap of $1.89 billion, a PE ratio of -1.98 and a beta of 1.33. Biohaven Ltd. has a one year low of $17.93 and a one year high of $55.70.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.29). On average, sell-side analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Insider Activity at Biohaven

In other Biohaven news, Director John W. Childs bought 32,700 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the purchase, the director now directly owns 2,320,571 shares in the company, valued at $70,707,798.37. This trade represents a 1.43 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 16.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on BHVN. JPMorgan Chase & Co. dropped their price target on shares of Biohaven from $72.00 to $68.00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 target price on shares of Biohaven in a research report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $54.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. Finally, Morgan Stanley cut their price objective on Biohaven from $69.00 to $63.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Fourteen equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Biohaven has an average rating of “Buy” and a consensus price target of $62.77.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.